LAFAYETTE, LA / ACCESS Newswire / March 4, 2026 / Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, today announced that its Board of Directors has authorized a share repurchase program effective through March 2027.
Under the share repurchase program, which constitutes a normal course issuer bid under applicable Canadian securities laws, Viemed may purchase up to 1,930,131 common shares of the Company (“the Common Shares”) from time to time in accordance with applicable securities laws, representing approximately 5% of the total issued and outstanding Common Shares as of March 4, 2026.
The Company intends to repurchase Common Shares through open market purchases, block purchases, or otherwise in accordance with applicable securities laws, including pursuant to Rule 10b-18 under the Securities Exchange Act of 1934, as amended. Subject to certain exceptions for block purchases, daily purchases will be limited to 25% of the average daily volume for the four calendar weeks preceding the date of purchase.
Casey Hoyt, Viemed’s Chief Executive Officer, noted, “Our Board’s authorization of a new share repurchase program reflects our confidence in the durability of our cash flows, the strength of our balance sheet, and our commitment to disciplined capital allocation. In 2025, we delivered record revenue and Adjusted EBITDA, more than doubled free cash flow year over year, and ended the year with effectively no net debt.
This authorization represents our fourth share repurchase program. Across our three prior programs, we returned approximately $26.3 million to shareholders through the repurchase of approximately 4.5 million shares. We view repurchases as an opportunistic and value-oriented component of our broader capital allocation framework, alongside continued investment in organic growth and selective acquisitions. With $13.5 million of cash on hand at year end and substantial availability under our credit facilities, we believe we are well positioned to execute on these priorities while maintaining strong financial flexibility.”
The price paid for the Common Shares will be the market price at the time of purchase plus applicable brokerage fees, or such other prices as may be permitted by applicable securities laws. There can be no assurance as to the precise number of Common Shares that will be repurchased under the program, if any. The Company may discontinue its purchases at any time, subject to compliance with applicable securities laws. The Common Shares purchased by the Company will be cancelled.
ABOUT VIEMED HEALTHCARE, INC.
Viemed is a provider of home medical equipment and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women’s health products and services. Viemed’s model emphasizes efficient, high-quality care delivered in the home through a combination of high-touch clinical support and technology-enabled services, including therapy, education, and counseling provided by our clinical practitioners. For more information, visit our website at www.viemed.com.
Forward-Looking Statements
Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company’s expectations regarding the share repurchase program, including the amount and timing of any repurchases of Common Shares, the funding sources for such repurchases, the availability of Common Shares for repurchase, and the anticipated benefits to shareholders, as well as statements regarding the durability of the Company’s cash flows, its capital allocation priorities, its ability to invest in organic growth and pursue acquisition opportunities, and its financial flexibility, are not historical facts and may constitute forward-looking statements. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns; and the use of artificial intelligence technologies; as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedarplus.ca. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.
LAFAYETTE, LA / ACCESS Newswire / March 4, 2026 / Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, announced today that it has reported its financial results for the three months and year ended December 31, 2025, and issued its guidance for the full year ending December 31, 2026.
Fourth Quarter and Full Year Operational Highlights (all dollar amounts are USD):
Net revenues for the quarter ended December 31, 2025 were a company record $76.2 million, an increase of $15.5 million, or 26%, over net revenues reported for the comparable quarter ended December 31, 2024. Total net revenues for the year ended December 31, 2025 were $270.3 million, an increase of $46.0 million, or 21%, over the year ended December 31, 2024, reflecting continued strong organic growth complemented by revenue contributions from our 2025 acquisition of Lehan’s Medical Equipment.
Net income attributable to Viemed for the quarter ended December 31, 2025 totaled $5.6 million, or $0.14 per diluted share, an increase of 31% over net income attributable to Viemed reported for the comparable quarter ended December 31, 2024. Net income attributable to Viemed for the year ended December 31, 2025 totaled $14.9 million, or $0.37 per diluted share, an increase of 33% over the year ended December 31, 2024, marking the Company’s ninth consecutive year of positive net income.
Adjusted EBITDA for the quarter and year ended December 31, 2025 totaled $18.2 million and a record $61.4 million, respectively.
The Company continued to generate strong free cash flow while delivering robust growth. Net cash provided by operating activities for the year ended December 31, 2025 totaled $51.9 million compared with $39.1 million for the year ended December 31, 2024. Free cash flow for the year ended December 31, 2025 totaled $28.1 million compared with $11.6 million for the year ended December 31, 2024.
The Company’s ventilator patient count totaled 12,259 as of December 31, 2025, an increase of 4% over December 31, 2024.
The Company increased its PAP therapy patient count to 34,528 as of December 31, 2025, an increase of 62% over December 31, 2024. The Company also increased its sleep resupply patient count to 36,561 as of December 31, 2025, an increase of 49% over December 31, 2024.
As of December 31, 2025, the Company maintained a cash balance of $13.5 million, and an overall working capital balance of $7.4 million. Long-term debt totaled $11.3 million and the Company had $46 million available under existing credit facilities.
Full Year 2026 Guidance (all dollar amounts are USD):
The Company is providing the following financial guidance for the year ending December 31, 2026:
Net revenue is expected to be in the range of $310 million to $320 million.
Adjusted EBITDA is expected to be in the range of $65 million to $69 million.
Net capital expenditures are expected to be in the range of 10% to 11.5% of net revenue.
See “Use of Non-GAAP Financial Information and Financial Guidance” below for further information about non-GAAP financial measures and non-GAAP financial guidance.
Casey Hoyt, Viemed’s Chief Executive Officer, commented, “Our 2025 performance reflects the continued strength of our technology-enabled home care model and the growing demand for high-quality chronic care management delivered in the home. We delivered strong double-digit organic growth by providing consistent, high-quality care that patients value and referral partners trust, driving deeper penetration across our markets. Leveraging our long-established nationwide payor network, we are expanding our maternal health offerings and extending our reach to serve more patients. With disciplined execution and platform-enhancing acquisitions, we enter 2026 with momentum and a clear focus on operational excellence, innovation, and long-term value creation.”
Todd Zehnder, Viemed’s Chief Operating Officer, added, “Our strong free cash flow generation and disciplined financial management continue to provide us with significant flexibility. Based on the strength of our balance sheet and our confidence in the durability of our cash flows, our Board has authorized a new share repurchase program for 2026. This authorization reflects our ongoing commitment to thoughtful capital allocation, allowing us to return capital to shareholders while continuing to invest in organic growth and strategic opportunities.”
Conference Call Details
The Company will host a conference call to discuss its fourth quarter and year end results, as well as its 2026 guidance, on Thursday, March 5, 2026 at 11:00 a.m. ET.
Interested parties may participate in the call by dialing:
Following the conclusion of the call, an audio recording and transcript of the call can be accessed on the Company’s website.
ABOUT VIEMED HEALTHCARE, INC.
Viemed is a provider of home medical equipment and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women’s health products and services. Viemed’s model emphasizes efficient, high-quality care delivered in the home through a combination of high-touch clinical support and technology-enabled services, including therapy, education, and counseling provided by our clinical practitioners. For more information, visit our website at www.viemed.com.
Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company’s net revenue and Adjusted EBITDA guidance for 2026 and capital allocation priorities, including share repurchases, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns; and the use of artificial intelligence technologies; as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedarplus.ca. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.
Use of Non-GAAP Financial Information and Financial Guidance
This press release includes references to financial measures that are calculated and presented using methodologies other than those in accordance with generally accepted accounting principles in the United States (“GAAP”), including Adjusted EBITDA and free cash flow. Any non-GAAP financial measures presented herein are intended to supplement, and not to be considered superior to or as a substitute for, the Company’s consolidated financial statements prepared in accordance with GAAP. These non-GAAP financial measures exclude significant expense and income items required by GAAP, and are subject to inherent limitations, including the exercise of judgment by management regarding which items to exclude or include. Non-GAAP measures presented herein may not be comparable to similarly titled measures presented by other companies. The reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are included in the tables accompanying this release.
This press release contains non-GAAP financial guidance. There is no reliable or reasonably estimable comparable GAAP measure for the Company’s non-GAAP financial guidance because the Company is not able to reliably predict the impact of certain items that typically have one or more of the following characteristics: highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. As a result, reconciliation of the non-GAAP financial guidance to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company’s future GAAP results. The Company’s financial guidance in this press release excludes the impact of potential future strategic acquisitions and any items that have not yet been identified or quantified. This guidance is subject to risks and uncertainties inherent in all forward-looking statements, as outlined above.
VIEMED HEALTHCARE, INC. CONSOLIDATED BALANCE SHEETS (Expressed in thousands of U.S. Dollars, except share amounts)
At
December 31, 2025
At
December 31, 2024
ASSETS
Current assets
Cash and cash equivalents
$
13,501
$
17,540
Accounts receivable, net
25,586
24,911
Inventory
5,047
4,320
Income tax receivable
227
–
Prepaid expenses and other assets
4,132
6,109
Total current assets
$
48,493
$
52,880
Long-term assets
Property and equipment, net
78,775
76,279
Finance lease right-of-use assets
–
50
Operating lease right-of-use assets
3,580
2,831
Equity investments
2,794
2,794
Deferred tax asset
5,289
8,398
Identifiable intangibles, net
1,285
848
Goodwill
58,938
32,989
Total long-term assets
$
150,661
$
124,189
TOTAL ASSETS
$
199,154
$
177,069
LIABILITIES
Current liabilities
Trade payables
$
7,333
$
5,322
Deferred revenue
7,520
6,694
Income taxes payable
–
3,883
Accrued liabilities
23,910
20,157
Finance lease liabilities, current portion
–
50
Operating lease liabilities, current portion
1,203
811
Current portion of long-term debt
1,090
409
Total current liabilities
$
41,056
$
37,326
Long-term liabilities
Accrued liabilities
922
846
Operating lease liabilities, less current portion
2,364
2,007
Long-term debt
11,291
3,589
Total long-term liabilities
$
14,577
$
6,442
TOTAL LIABILITIES
$
55,633
$
43,768
Commitments and Contingencies
–
–
SHAREHOLDERS’ EQUITY
Common stock – No par value: unlimited authorized; 38,019,082 and 39,132,897 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively
16,912
23,365
Additional paid-in capital
21,742
18,337
Retained earnings
102,891
89,691
TOTAL VIEMED HEALTHCARE, INC.’S SHAREHOLDERS’ EQUITY
$
141,545
$
131,393
Noncontrolling interest in subsidiary
1,976
1,908
TOTAL SHAREHOLDERS’ EQUITY
143,521
133,301
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
$
199,154
$
177,069
VIEMED HEALTHCARE, INC. CONSOLIDATED STATEMENTS OF INCOME (Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts)
Three Months Ended December 31,
Year Ended December 31,
2025
2024
2025
2024
Revenue
$
76,181
$
60,695
$
270,280
$
224,257
Cost of revenue
32,078
24,557
114,822
91,054
Gross profit
$
44,103
$
36,138
$
155,458
$
133,203
Operating expenses
Selling, general and administrative
32,219
28,211
121,366
106,199
Research and development
598
803
3,017
3,068
Stock-based compensation
2,300
1,521
9,132
6,285
Depreciation and amortization
387
343
1,485
1,483
Loss (gain) on disposal of property and equipment
289
(1,104
)
(2,239
)
(1,905
)
Other expense (income), net
(61
)
(88
)
(252
)
173
Income from operations
$
8,371
$
6,452
$
22,949
$
17,900
Non-operating income and expenses
Income (loss) from investments
–
–
–
(954
)
Interest expense, net
(364
)
(147
)
(1,182
)
(776
)
Net income before taxes
8,007
6,305
21,767
16,170
Provision for income taxes
2,191
1,881
6,391
4,761
Net income
$
5,816
$
4,424
$
15,376
$
11,409
Net income attributable to noncontrolling interest
177
108
442
144
Net income attributable to Viemed Healthcare, Inc.
$
5,639
$
4,316
$
14,934
$
11,265
Net income per share
Basic
$
0.15
$
0.11
$
0.38
$
0.29
Diluted
$
0.14
$
0.10
$
0.37
$
0.28
Weighted average number of common shares outstanding:
Basic
38,018,546
39,027,522
38,895,228
38,754,893
Diluted
40,156,552
41,522,457
40,823,823
40,805,085
VIEMED HEALTHCARE, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Expressed in thousands of U.S. Dollars)
Year Ended December 31,
2025
2024
Cash flows from operating activities
Net income
$
15,376
$
11,409
Adjustments for:
Depreciation and amortization
28,613
25,368
Stock-based compensation expense
9,132
6,285
Distributions of earnings received from equity method investments
–
147
Income from equity method investments
–
(261
)
Loss (income) from debt investment
–
1,344
Loss (gain) on disposal of property and equipment
(2,239
)
(1,905
)
Amortization of deferred financing costs
228
187
Deferred income tax expense (benefit)
3,109
(3,840
)
Changes in working capital:
Accounts receivable, net
1,158
(6,073
)
Inventory
59
574
Prepaid expenses and other assets
(503
)
544
Trade payables
479
359
Deferred revenue
359
364
Accrued liabilities
255
2,857
Income tax payable/receivable
(4,110
)
1,730
Net cash provided by operating activities
$
51,916
$
39,089
Cash flows from investing activities
Purchase of property and equipment
(39,985
)
(37,771
)
Investment in equity investments
–
(1,000
)
Cash paid for acquisitions, net of cash acquired
(26,332
)
(2,999
)
Proceeds from sale of debt security
–
750
Proceeds from sale of property and equipment
16,151
10,321
Net cash used in investing activities
$
(50,166
)
$
(30,699
)
Cash flows from financing activities
Proceeds from exercise of options
1,439
1,017
Proceeds from term notes
9,000
–
Principal payments on term notes
(730
)
(1,071
)
Proceeds from revolving credit facilities
13,000
3,000
Principal payments on revolving credit facilities
(13,000
)
(5,000
)
Payments for debt issuance costs
(115
)
(192
)
Shares redeemed to pay income tax
(1,734
)
(1,069
)
Shares repurchased under the share repurchase program
(13,225
)
–
Repayments of finance lease liabilities
(50
)
(338
)
Distributions to non-controlling interest
(374
)
(36
)
Net cash used in financing activities
$
(5,789
)
$
(3,689
)
Net increase (decrease) in cash and cash equivalents
(4,039
)
4,701
Cash and cash equivalents at beginning of year
17,540
12,839
Cash and cash equivalents at end of period
$
13,501
$
17,540
Supplemental disclosures of cash flow information
Cash paid during the period for interest
$
874
$
950
Cash paid during the period for income taxes, net of refunds
$
7,390
$
6,827
Supplemental disclosures of non-cash transactions
Equipment and other fixed asset purchases payable at end of period
$
3,221
$
2,179
Equipment sales receivable at end of period
$
–
$
2,844
Non-cash consideration received for sale of debt security
$
–
$
125
Reconciliation from GAAP Net Income to Non-GAAP Adjusted EBITDA
This press release refers to “Adjusted EBITDA”, which is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). Adjusted EBITDA should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Management believes Adjusted EBITDA provides helpful information with respect to the Company’s operating performance as viewed by management, including a view of the Company’s business that is not dependent on the impact of the Company’s capitalization structure and items that are not part of the Company’s day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company’s operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company’s employees, (iii) for planning purposes, including the preparation of the Company’s internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company’s operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company’s operating performance in the same manner as management. Adjusted EBITDA is not a measurement of the Company’s financial performance under GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with GAAP. Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of the Company’s operating results as reported under GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters the Company considers not to be indicative of ongoing operations; and other companies in the Company’s industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure. In calculating Adjusted EBITDA, certain items (mostly non-cash) are excluded from net income attributable to Viemed Healthcare, Inc., including depreciation and amortization of capitalized assets, net interest expense, stock based compensation, transaction costs, impairment of assets, and taxes.
The following unaudited table is a reconciliation of net income attributable to Viemed Healthcare, Inc., the most directly comparable GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:
(Expressed in thousands of U.S. Dollars)
For the quarter ended
December 31, 2025
September 30, 2025
June 30, 2025
March 31, 2025
December 31, 2024
September 30, 2024
June 30, 2024
March 31, 2024
Net Income attributable to Viemed Healthcare, Inc.
$
5,639
$
3,513
$
3,157
$
2,625
$
4,316
$
3,878
$
1,468
$
1,603
Add back:
Depreciation & amortization
7,570
7,539
6,891
6,613
6,366
6,408
6,309
6,285
Interest expense, net
364
507
132
179
147
225
254
150
Stock-based compensation(a)
2,300
2,180
2,341
2,311
1,521
1,712
1,620
1,432
Transaction costs(b)
139
847
53
85
11
12
221
110
Impairment of assets(c)
–
–
–
–
–
125
2,173
–
Income tax expense
2,191
1,535
1,713
952
1,881
1,594
768
518
Adjusted EBITDA
$
18,203
$
16,121
$
14,287
$
12,765
$
14,242
$
13,954
$
12,813
$
10,098
For the year ended
December 31, 2025
December 31, 2024
Net Income attributable to Viemed Healthcare, Inc.
$
14,934
$
11,265
Add back:
Depreciation & amortization
28,613
25,368
Interest expense, net
1,182
776
Stock-based compensation(a)
9,132
6,285
Transaction costs(b)
1,124
354
Impairment of assets(c)
–
2,298
Income tax expense
6,391
4,761
Adjusted EBITDA
$
61,376
$
51,107
(a) Represents non-cash, equity-based compensation expense associated with option and RSU awards. (b) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions. (c) Represents impairments of the fair value of investment and litigation-related assets.
Reconciliation from GAAP Net Cash Provided by Operating Activities to Non-GAAP Free Cash Flow
This press release refers to “free cash flow” which is a non-GAAP financial measure that does not have a standardized meaning prescribed by GAAP. Free cash flow is defined as net cash provided by operating activities less net capital expenditures (“Net CAPEX”). Net CAPEX is calculated as purchases of property and equipment minus proceeds from the sale of property and equipment. The Company’s presentation of this financial measure may not be comparable to similarly titled measures used by other companies.
The Company presents free cash flow as a supplemental liquidity measure. Management believes free cash flow provides investors with useful insight into the Company’s ability to generate cash, fund growth initiatives, and return capital to shareholders.
The following unaudited table is a reconciliation of net cash provided by operating activities, the most directly comparable U.S. GAAP measure, to free cash flow on a historical basis for the periods indicated:
Year Ended December 31,
(in thousands)
2025
2024
Net cash provided by operating activities
$
51,916
$
39,089
Less:
Purchase of property and equipment
(39,985
)
(37,771
)
Proceeds from sale of property & equipment
16,151
10,321
Net CAPEX
(23,834
)
(27,450
)
Free cash flow
$
28,082
$
11,639
The revenues from each major source are summarized in the following table:
LOS ANGELES, CA / ACCESS Newswire / March 4, 2026 / Pacific Avenue Capital Partners (“Pacific Avenue”), a Los Angeles-headquartered private equity firm focused on complex corporate carve-outs and other operationally intensive situations in the middle market, today announced that an affiliate has completed the acquisition of Columbus McKinnon Corporation’s (“Columbus McKinnon”, NASDAQ:CMCO) U.S. based power chain hoist and chain business (the “Company”), including its associated international sales support functions.
Upon the closing of the transaction, the business will move forward under the name Stuart Rush, representing a new chapter built on decades of engineering excellence, award-winning products, and trusted customer relationships. The name Stuart Rush speaks to the business’s heritage and connection between its two original manufacturing sites in Damascus, Virginia and Lexington, Tennessee. These two locations have long worked hand-in-hand to develop a portfolio of highly regarded brands including Lodestar® and Lodestar ET™, Budgit®, Chester®, Coffing® (including the JLC and EC lines), Cyclone®, CM Puller®, Powerstar®, Prostar®, Valustar®, Shopstar®, ShopAir™, the innovative BatteryStar®, and Herc-Alloy® chain solutions with strong positions across industrial, construction, defense, and entertainment end markets.
Stuart Rush operates a primary manufacturing and engineering facility in Damascus, Virginia, a vertically integrated chain manufacturing facility in Lexington, Tennessee, and a leased training and production facility in Rock Lititz, Pennsylvania serving its Lodestar® brand and entertainment customers. In connection with the acquisition, the Company will open a new location near Chester in the United Kingdom to better serve the UK, European, and Asia-Pacific markets, while investing growth capital to expand capacity and capabilities in Damascus. Its products are widely recognized for reliability, safety, and performance in mission-critical lifting applications.
As it transitions to a standalone business, Stuart Rush will operate with a renewed strategic and operational focus, prioritizing its employees and customers in the power chain hoist and chain markets. With support from Pacific Avenue, Stuart Rush plans to increase investment in product innovation, supply chain resilience, and customer service.
“We are excited to welcome Stuart Rush into the Pacific Avenue portfolio in Fund I,” said Chris Sznewajs, Founder and Managing Partner of Pacific Avenue Capital Partners. “Our ability to be a solutions provider to Columbus McKinnon was a difference maker in this complex carve out. Pacific Avenue prides itself on working with corporate sellers to address the most complex transactions, and this is a great example of that. Stuart Rush reflects the powerful connection between its market-leading hoist and chain platforms. These brands have supported customers in critical industries for decades, and we look forward to investing behind innovation, operational excellence, and customer partnership as Stuart Rush grows as an independent enterprise.”
About Pacific Avenue Capital Partners Pacific Avenue Capital Partners is a global private equity firm, headquartered in Los Angeles with offices in Paris, France. The firm is focused on corporate divestitures and other complex situations in the middle market. Pacific Avenue has extensive M&A and operations experience, allowing the firm to navigate complex transactions and unlock value through operational improvement, capital investment, and accelerated growth. Pacific Avenue takes a collaborative approach in partnering with strong management teams to drive lasting and strategic change while assisting businesses in reaching their full potential. Pacific Avenue has approximately $3.8 billion of Assets Under Management (AUM) as of September 30, 2025. The members of the Pacific Avenue team have closed over 120 transactions, including over 50 corporate divestitures, across a multitude of industries throughout their combined careers. For more information, please visit https://pacificavenuecapital.com/.
About Columbus McKinnon Columbus McKinnon Corporation (NASDAQ:CMCO) is a leading designer, manufacturer, and marketer of intelligent motion solutions for material handling. Through a portfolio of well-known brands, Columbus McKinnon helps customers improve efficiency, safety, and performance in demanding industrial and commercial applications worldwide. For more information, visit www.columbusmckinnon.com.
TORONTO, ONTARIO / ACCESS Newswire / March 4, 2026 / Canada’s rental housing market is undergoing a quiet but seismic transformation. Across the country’s largest cities – Toronto, Vancouver, Calgary, and Ottawa – a new asset class is emerging that is fundamentally changing how rental homes are designed, financed, and delivered: build-to-rent (BTR). Unlike traditional condominium projects where individual investors purchase units and lease them independently, build-to-rent developments are purpose-engineered from the ground up to serve long-term renters, owned and operated by a single institutional landlord. For Ladan Hosseinzadeh Sadeghi, President & CEO of Sky Property Group Inc., the rise of BTR represents one of the most significant structural shifts in Canadian real estate in a generation.
“Build-to-rent is not just a new product type – it’s a paradigm shift in how we think about housing delivery in Canada,” says Ladan Hosseinzadeh Sadeghi. “When a building is designed specifically for renters from day one, every decision – from unit layouts and soundproofing to amenity programming and building management – is optimized for the renter experience rather than the resale market. The result is a fundamentally superior product for Canadian families.”
A Market Born From Necessity
The BTR sector’s rise in Canada is directly tied to the country’s deepening rental housing crisis. Canada’s vacancy rate in major urban centres has hovered near historic lows, while rising mortgage rates and elevated home prices have kept millions of Canadians in the rental market longer than they anticipated. The traditional condominium investor model – where individual speculators purchase pre-construction units and rent them out – has proven increasingly fragile. As interest rates climbed through 2023 and 2024, thousands of condo investors found their carrying costs exceeding rental income, reducing the flow of new rental supply just as demand intensified.
BTR addresses this gap by bringing institutional capital and professional management into the rental supply chain. Pension funds, real estate investment trusts (REITs), and large private developers are now partnering with municipalities across Canada to deliver purpose-designed rental communities at scale.
“The condo investor model worked well when financing was cheap, but it was never reliable as a housing policy tool,” explains Ladan Hosseinzadeh Sadeghi. “Build-to-rent changes the equation entirely. When institutional capital is behind a rental project, the units stay rental – permanently. That kind of long-term supply commitment is exactly what Canadian cities need right now.”
Institutional investors are increasingly recognizing Canadian rental housing as a compelling asset class.
What Sets BTR Apart
The differences between a BTR community and a conventional rental building – even a purpose-built one – are substantial. BTR projects in Canada are increasingly offering larger-format units suited to families: two- and three-bedroom configurations with dedicated storage, in-suite laundry, and flexible living spaces that traditional purpose-built rental buildings historically underdelivered. Amenities often rival or exceed those found in luxury condominiums – co-working lounges, pet-friendly outdoor spaces, concierge services, and community programming designed to build long-term tenant retention.
From an investor perspective, the BTR model offers attractive risk-adjusted returns: lower vacancy rates driven by high-quality design and management, stable long-term income streams, and the operational efficiency that comes from unified ownership and management. These characteristics have made BTR an increasingly preferred allocation for Canada’s large pension funds, several of which have already announced significant BTR commitments in the Greater Toronto Area and Metro Vancouver.
“What we’re seeing from institutional investors is a recognition that Canadian rental housing is not just a social need – it’s a compelling, recession-resilient asset class,” says Ladan Hosseinzadeh Sadeghi. “Canada has chronic undersupply, strong population growth, and a regulatory environment that is slowly but meaningfully improving for rental developers. The fundamentals are exceptional.”
Build-to-rent units are designed with premium finishes and family-friendly layouts from the ground up.
Municipal Policy Is Opening the Door
One of the most meaningful enablers of BTR growth in Canada has been evolving municipal policy. Cities like Toronto and Ottawa have introduced zoning reforms, fee deferrals, and streamlined permitting pathways specifically designed to incentivize rental construction over condominium development. The federal government’s removal of GST on purpose-built rental construction – a landmark policy change – has further improved the economics of BTR projects, reducing total development costs by three to five percent in many markets.
Still, Ladan Hosseinzadeh Sadeghi cautions that policy progress must continue to accelerate if BTR is to deliver its full potential for Canadian renters.
“The GST exemption was a game-changer, but development charges remain a significant burden on rental projects in municipalities across Ontario and British Columbia,” she says. “Municipalities that want to attract institutional rental investment need to take development charges seriously. A purpose-built rental building serving 300 Canadian families should not face the same fee structure as a luxury condominium. Policy alignment matters.”
Sky Property Group Inc. has been an active voice in advocating for policy environments that support rental supply growth, working with municipal planning departments and housing advocacy groups to help shape zoning and incentive frameworks that are practical for developers and equitable for renters.
Purpose-built rental communities are transforming Canadian urban landscapes.
The Road Ahead
Market analysts project that Canada’s BTR sector – still nascent compared to the United Kingdom and Australia, where build-to-rent has matured into a multi-hundred-billion-dollar industry – could deliver tens of thousands of new rental units annually within the next decade if regulatory and financing conditions remain supportive. For Ladan Hosseinzadeh Sadeghi, the trajectory is clear: BTR is not a niche experiment but the future of rental housing delivery in Canada.
“Canada has a rare opportunity right now,” she says. “We’re early enough in the build-to-rent cycle that we can learn from mature markets abroad and design this sector thoughtfully – with tenant protections baked in, with genuine affordability components, and with long-term community building at the center of the model. That’s the version of build-to-rent that will make Canada’s cities stronger.”
As the country continues to grapple with its housing affordability crisis, voices like Ladan Hosseinzadeh Sadeghi’s – grounded in development practice and informed by policy – are essential to shaping a rental market that works for all Canadians.
—————————————-
About Sky Property Group Inc. Sky Property Group Inc. is a Toronto-based real estate development and property management company with deep expertise in urban intensification, land assembly, and residential development across the Greater Toronto Area. Led by President & CEO Ladan Hosseinzadeh Sadeghi, Sky Property Group is committed to building communities that serve the long-term needs of Canadian cities.
NEW YORK CITY, NEW YORK / ACCESS Newswire / March 4, 2026 / As geopolitical tensions rise, supply chains face unprecedented pressure, and global markets navigate an increasingly unpredictable environment, organizations worldwide are reassessing how they protect assets, ensure continuity, and maintain trust. SMX, headquartered in Singapore with a growing regional footprint across Southeast Asia, continues to demonstrate why resilient, science‑based material authentication technologies are essential tools for navigating today’s destabilized landscape.
Operating From Regional Stability
With headquarters in Singapore-one of the world’s most stable political, economic, and regulatory environments-SMX benefits from Southeast Asia’s relative insulation from many of the disruptions affecting other global regions. The company’s strategic position allows it to focus on execution, expand its technological capabilities, and support industries seeking dependable partners amid uncertainty.
Southeast Asia continues to strengthen its role as a global trade corridor, and SMX’s presence within this ecosystem positions it to support companies that require certainty, continuity, and verifiable supply‑chain integrity.
Technology Designed for Real‑World Risk
In times of conflict, regional disruption, and shifting alliances, the security and traceability of physical assets become more critical than ever. SMX’s technology is built on a material‑embedded tagging and digital‑twin system that allows companies to mark, track, and verify items throughout their entire lifecycle.
This system provides value across multiple sectors:
Supply‑Chain Security: SMX helps organizations authenticate materials and components from origin to delivery, reducing exposure to substitution, fraud, and tampering during periods when global logistics networks are strained.
Critical Materials Protection: As markets face pressure on commodities and energy-related resources, SMX’s solutions help stakeholders verify the provenance and movement of metals, minerals, and other essential inputs.
Defense and High‑Security Asset Assurance: In environments where the protection of essential goods becomes paramount, SMX enables higher levels of tracking accuracy, chain‑of‑custody documentation, and asset verification.
Sustainability and Circularity: Even during global instability, regulatory and consumer expectations around environmental responsibility remain high. SMX’s technology supports companies in proving recycling rates, verifying sustainable practices, and ensuring compliance with evolving standards.
Consumer and Brand Protection: In uncertain periods, counterfeit products often proliferate. SMX provides authentication solutions that help protect brands, consumers, and market trust.
These capabilities address core vulnerabilities that become amplified during conflict, market volatility, or major geopolitical shifts-providing organizations with confidence in what they produce, move, store, and rely on.
Supporting Peace‑Oriented and Stability‑Focused Investment Ecosystems
SMX’s relationships and presence across the UAE and broader Mediterranean‑to‑Asia trading corridor align with regions increasingly oriented toward long‑term stability and economic diversification. These markets continue to invest in peace-driven initiatives, secure logistics platforms, and infrastructure designed to withstand geopolitical risk.
As companies across these regions adopt more secure supply‑chain practices and higher verification standards, SMX’s technology provides the digital and material backbone needed to support these goals. The company’s solutions reinforce compliance, build trust across borders, and strengthen the reliability of regional trade networks.
Invested, Protected, and Positioned for Measured Growth
Through consistent investment in its technology, data infrastructure, and operational readiness, SMX has built a foundation designed to support scale, continuity, and long-term growth. The company has taken steps to protect its intellectual property, reinforce its operational resilience, and remain focused on execution-ensuring it can meet the evolving needs of both regional and global stakeholders.
SMX’s approach is centered on long-term value creation: solving fundamental, real-world challenges that persist regardless of market cycles. By providing a platform that improves transparency, strengthens asset protection, and reduces risk exposure, SMX contributes solutions that remain essential even in periods of economic or geopolitical instability.
A Practical Path Forward
As industries navigate shifting energy markets, conflict-driven disruptions, supply-chain uncertainty, and evolving compliance expectations, SMX continues to offer tools that enhance clarity, trust, and operational certainty. With stable regional grounding, a globally relevant technology platform, and a commitment to responsible and transparent execution, SMX remains positioned to support organizations seeking resilience in an unstable world.
This version of the Press Release includes numerous updates
Natarajan strengthens executive client leadership as Assembly scales in North America
NEW YORK CITY, NEW YORK / ACCESS Newswire / March 4, 2026 / Assembly, the global media agency within the Stagwell network famous for making brands perform, has appointed Aruna Natarajan as Chief Client Officer, North America, as the agency expands its client portfolio across the region. Based in New York, Natarajan will report to Jill Kelly, CEO of Assembly North America.
As marketers push for faster, more technology-connected delivery across channels and audiences, Assembly is further strengthening its senior client leadership bench to match the pace and complexity of modern client partnerships. Natarajan will focus on deepening executive relationships, sharpening how teams align to client business priorities, and reinforcing consistent partnership standards across North America.
Her remit spans the full client lifecycle, including account stewardship, client governance, and the operational excellence that supports retention and organic growth. She will work closely with Global Chief Client Officer Andrea Timmerman.
Natarajan joins from WPP Media, where she served as Chief Operating Officer and previously Chief Client Officer, leading large global portfolios and working with senior marketers through transformation and growth.
“Aruna is a standout client leader with the experience to match the scale and ambition of this moment for Assembly in North America,” said Jill Kelly, Assembly North America CEO. “As we continue to grow, her leadership will help us deepen executive partnerships and continue to raise the bar on what clients expect from us as their media and technology partner.”
Natarajan said her priority is scaling a client leadership approach built on trust, clarity, and measurable outcomes.
“The opportunity at Assembly is to continue to elevate client leadership as a practice into true business partnership with clients,” said Natarajan. “That means building trust, developing a deep understanding of their businesses, and identifying how media can unlock growth for their brands. I’m excited to help establish and scale this client leadership practice alongside Jill and the Assembly team.”
ABOUT ASSEMBLY
Assembly is a global omnichannel agency built for brands that want a more modern approach to building brands that perform. Backed by the Stagwell network, we are a literal assembly of data, talent, and technology built to unlock smarter, faster, and better-performing outcomes from the bottom up -not the top down. Curious, collaborative, and driven by change, we are an agency of builders who believe the better the experience, the better the performance. We don’t see brand and performance as an either/or. For us, it’s always both. The + symbol in our logo, known as the ORAD, represents this mindset. It’s a mark of how we think, how we build, and how we deliver results across the full funnel. Assembly’s foundation is built on three core elements: our purpose-built STAGE Experience Engine, the strategic product it powers-Brand Performance Planning (BPP) – and an organizational design built for speed, depth, and the demands of modern marketing. Together, they enable us to build better brand experiences that reimagine how brands connect, engage, and grow across data, tech, media, creative and commerce. With over 3,000 experts in 44 offices worldwide, Assembly delivers full-funnel solutions that help the world’s most ambitious brands perform. Learn more at assemblyglobal.com.
HOUSTON, TX / ACCESS Newswire / March 4, 2026 / BrYet US, Inc. (“BrYet”) – a biotechnology innovator focused on developing curative therapies for advanced cancers – announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its lead drug, ML-016. Upon approval, the IND will support the expansion of BrYet’s ML-016 clinical program with additional trials in the United States.
“Submitting our first IND application is a major step forward for BrYet, bringing us closer to delivering new therapeutic options for advanced cancer patients worldwide,” said Dr. Mauro Ferrari, President and CEO of BrYet. “This milestone reflects decades of scientific research behind our unique approach to treating cancer, based on our proprietary platform for targeting phenotypes.”
Last year, BrYet received Australian approval to begin its first-in-human clinical study of ML-016. The broadly scoped Phase I/II trial will enroll patients with any primary or metastatic cancer involving the lungs or liver, with the first patient dose expected to be administered in the second quarter of 2026. The U.S. IND will expand the clinical program with a focus on specific indications.
ML-016 has shown strong therapeutic efficacy in preclinical models, achieving long-term survival in about 50% of test animals in multiple metastatic tumor models. GLP preclinical data reconfirmed the strong safety profile of ML-016 and BrYet’s platform for targeting phenotypes.
About ML-016
ML-016 is comprised of an amino acid polymer conjugated to doxorubicin with a formulation that includes BrYet’s proprietary Si-PlateloidTM technology, designed to target the vascular endothelium of blood vessels in the tumor microenvironment. The amino acid-drug conjugate is released into the tumor, where it forms exosome-like vesicles.
These “exosomoids” are designed to be preferentially taken up by cancer cells including those that have previously been resistant to therapy. Through the mechanisms of cellular trafficking, the exosomoid vesicles are intended to be transported to late-stage endosomes and lysosomes, where the increased acidity releases the cytotoxic agent into the cell nucleus.
About BrYet US, Inc. BrYet is a privately held biotechnology company developing potentially first-in-class therapies for patients suffering from cancers for which there is no current curative treatment. BrYet’s lead asset, ML-016, is being developed for cancers of the lungs and liver, including advanced primary malignancies and metastatic spread from primary cancer that originates in other organs or tissue of the body. The company’s fundamental belief is that upon localization in the lungs and liver, these cancers acquire molecular transport phenotypes that are conserved regardless of site of origin and are largely independent of molecular mutations and their continued evolution. BrYet designs multi-component new chemical entities and formulations, which are directed against the fundamental aspects of these cancer-associated, organ-specific transport phenotypes. The company’s proprietary platforms include the Si-PlateloidTM and the mathematical formalism for designing the multi-component drugs, termed Transport Oncophysics. BrYet believes that similar approaches may provide advances against other forms of presently incurable cancers, as well as other pathologies of the lungs and liver. For more information about BrYet, please visit the company’s website: https://bryetpharma.com/
Safe-Harbor Statement
This press release contains forward-looking statements concerning BrYet and its business. These statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in this document, the words “expects,” “anticipates,” “estimates,” “intends,” “believes,” “plans,” “predicts,” “should,” “could,” “will,” and similar expressions are intended to identify forward-looking statements.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ from expectations. Factors that could contribute to these differences include the results of studies and clinical trials, regulatory approvals, challenges in clinical trials, the ability to retain employees, research and development expenses, reliance on third parties, intellectual property issues, competition, future funding needs, economic conditions, and other industry-specific risks. You should not place undue reliance on these statements, which are current as of the date of this press release. BrYet does not plan to update these statements unless legally required.
Media & Investor Contact BrYet US, Inc. 2450 Holcombe Blvd., Suite 1520, Houston, TX 77021, USA info@bryetpharma.com
BROOKLYN, NY / ACCESS Newswire / March 4, 2026 / IEH Corporation (OTCQX:IEHC) announced today that its order backlog has reached an all-time high, due primarily to the increased demand for precision-guided munitions, missiles and air defense systems that employ IEH’s Hyperboloid connectors.
Dave Offerman, President and CEO of IEH Corporation commented, “Due to the overwhelming demand for the various defense systems that utilize our Hyperboloid connectors, contacts and interconnect assemblies, our backlog is now the highest it’s ever been. It has more than doubled in the last 12 months and has increased nearly 30% in just the first two months of 2026. This backlog will translate into revenue over the next 12-18 months.
Defense programs like PATRIOT, AMRAAM, THAAD, APKWS and MARK-48 all employ our interconnect solutions in their missiles, radars, and precision-guided munitions, and rely on IEH to supply the connectors that enable these critical programs. As these systems are deployed in greater volume and frequency, and the US prioritizes equipment replenishment in support of our warfighting capabilities, we expect demand to continue. As we have throughout our long history, IEH stands ready to support our nation’s defense and that of our valued allies.”
About IEH Corporation
For 80 years and 4 generations of family-run management, IEH Corporation has designed, developed, and manufactured printed circuit board (PCB) connectors, custom interconnects and contacts for high performance applications. With its signature Hyperboloid technology, IEH supplies the most durable, reliable connectors for the most demanding environments. The company markets primarily to companies in defense, aerospace, space and industrial applications, in the United States, Canada, Europe, Southeast and Central Asia and the Mideast. The company was founded in 1941 and is headquartered in Brooklyn, New York.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this press release, and in related comments by the Company’s management, include “forward-looking statements.” All statements, other than statements of historical facts, including, without limitation, statements or expectations regarding our financial condition, statements or expectations regarding our revenues, cash and backlog, expectations regarding future cash requirements, revenue and revenue recovery, including for fiscal year 2026 and beyond are forward-looking statements. These statements often include words such as “believe,” “expect,” “estimate,” “plan,” “will,” “may,” “would,” “should,” “could,” or similar expressions, although not all forward-looking statements contain such identifying words. These statements are based on certain assumptions that the Company has made on its current expectations and projections about future events. The Company believes these judgments are reasonable, but you should understand that these statements are not guarantees of performance or results, and you should not place undue reliance on any forward-looking statements. The Company’s actual performance or results could differ materially from those expressed in the forward-looking statements due to a variety of important factors, both positive and negative, as they will depend on many factors about which we are unsure, including many factors beyond our control. Among other items, such factors could include: our ability to reduce costs or increase revenue; changes in the macroeconomic environment or in the finances of our customers; changes in accounting principles, or their application or interpretation, and our ability to make accurate estimates and the assumptions underlying the estimates; our ability to attract and retain key employees and key resources; and other risk factors discussed from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on June 12, 2025, and in subsequent reports filed with or furnished to the SEC. Additional information concerning these and other factors can be found in our filings with the SEC. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking statements contained in this press release as a result of new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in our filings with the SEC that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business.
NEW YORK CITY, NEW YORK / ACCESS Newswire / March 4, 2026 / Assembly, the global media agency built for brand performance within the Stagwell network, today announced the appointment of Aruna Natarajan as Chief Client Officer, North America. Based in New York, Natarajan will report to Jill Kelly, CEO of Assembly North America.
In this role, Natarajan will oversee the growth and health of Assembly’s client relationships across North America, with responsibility for retention, organic growth, and operational excellence. She will evolve how Assembly partners with clients-building a more modern, technology‑enabled approach to client service that deepens value, strengthens long‑term partnerships, and supports sustainable growth.
Natarajan’s mandate includes defining what great partnership looks like across client contracting, governance, and service delivery. She will establish clear standards that ensure consistency, rigor, and scalability across every engagement, advancing Assembly’s operational foundation while optimizing how teams are structured and resourced to deliver measurable business outcomes. A key focus for Natarajan will be developing a more contemporary model for profitable growth; one that moves beyond legacy FTE and commission structures toward value-driven approaches that align talent, performance, and client success.
Natarajan joins Assembly from WPP Media, where she most recently served as Chief Operating Officer, and previously as Chief Client Officer. In those roles, she led large‑scale client portfolios, oversaw complex global operations, and partnered closely with senior marketers navigating transformation and growth. With her combined experience across client leadership and operational execution, Aruna brings a unique perspective to the role with the proven ability to build systems that sustain both performance and partnership.
“Aruna is a proven client leader who understands what it takes to deliver consistent value at scale,” said Jill Kelly, CEO of Assembly North America. “She brings rare fluency across client leadership, operating models, and growth strategies. Her remit is simple and ambitious: make our clients stronger, help them grow, and elevate what great partnership means at Assembly.”
In her new role, Natarajan will oversee Assembly’s North America Client Experience Leadership team and collaborate closely with Global Chief Client Officer, Andrea Timmerman.
“The opportunity at Assembly is to elevate client leadership as a practice into true business partnership with clients,” said Aruna Natarajan. “That means building trust, developing deep understanding of their business and identifying how media can unlock growth for their brands. I am excited to help establish and scale this client leadership practice alongside Jill and the Assembly team.
ABOUT ASSEMBLY
Assembly is a global omnichannel agency built for brands that want a more modern approach to building brands that perform. Backed by the Stagwell network, we are a literal assembly of data, talent, and technology built to unlock smarter, faster, and better-performing outcomes from the bottom up -not the top down. Curious, collaborative, and driven by change, we are an agency of builders who believe the better the experience, the better the performance. We don’t see brand and performance as an either/or. For us, it’s always both. The + symbol in our logo, known as the ORAD, represents this mindset. It’s a mark of how we think, how we build, and how we deliver results across the full funnel. Assembly’s foundation is built on three core elements: our purpose-built STAGE Experience Engine, the strategic product it powers-Brand Performance Planning (BPP) – and an organizational design built for speed, depth, and the demands of modern marketing. Together, they enable us to build better brand experiences that reimagine how brands connect, engage, and grow across data, tech, media, creative and commerce. With over 3,000 experts in 44 offices worldwide, Assembly delivers full-funnel solutions that help the world’s most ambitious brands perform. Learn more at assemblyglobal.com.
With deep expertise backed by $270 billion in valuations, Eqvista Real-Time Company Valuation® platform is set to value over $1 trillion in private company assets by 2026 – revolutionizing how the vast, fragmented private market is understood, accessed, and valued.
SAN FRANCISCO, CA / ACCESS Newswire / March 4, 2026 / Eqvista, the leading equity management and valuation platform for private companies, has launched Eqvista Real-Time Company Valuation®, an AI-powered share price discovery for private companies, built on $270B+ of valuation experience – the foundation for liquidity, transparency, and modern equity infrastructure.
Designed to bring Wall Street-level transparency to the private market, Real-Time Valuation gives companies the ability to instantly calculate and monitor their share value – with updates in real time, not yearly.
“We’ve already valued over $270 billion in private company assets,” said Tomas Milar, Founder and CEO of Eqvista. “And we’re just getting started. Our next milestone is $1 trillion in real-time valuations – and we believe we’ll get there by transforming how the private market operates. Yahoo Finance unlocked access to real-time stock prices for public companies. NASDAQ gave them the trust layer to move capital. Eqvista is doing both – for the private market. While others debate how to unlock liquidity, we started with the only thing that makes it possible: price.“
Replacing Outdated PDFs with Living Valuations
Traditional 409A and FMV valuations are delivered via static PDFs that often take weeks to produce – and are obsolete by the time they arrive. Eqvista’s Real-Time Valuation replaces that model with an intelligent system that updates dynamically as company data changes, combining advanced AI models with live data from public and private market transactions.
Benefits include:
Access to Capital, Supercharged – Get real-time Fair Market Value during fundraising-whether SAFEs, convertible notes, or equity rounds from Seed to pre-IPO.
Secondary Market Ready – Publish your FMV online to prevent undervaluation and build trust in your shares.
Liquidity for Shareholders – Simplify and clarify secondary transactions with always-available real-time valuations.
In Real-Time – Instantly know your company’s worth – no waiting, smarter decisions, and greater investor confidence.
409A and ESOP Clarity – Stay compliant with up-to-date audit-ready 409a valuations for ESOPs – clear, unambiguous and accessible to all stakeholders.
Rewiring the Private Market
With over 6 million private companies in the U.S. alone – representing more than half of the national GDP – the need for dynamic, reliable valuation tools has never been greater. Eqvista’s platform gives founders, CFOs, boards, and investors the ability to make capital decisions with clarity and confidence.
“The public market has tickers. We believe the private market deserves the same real-time intelligence,” said Tomas Milar, Founder and CEO of Eqvista “Valuation is no longer just a report – it’s infrastructure. We’ve built the first real-time pricing system for private equities, AI-powered and delivered by humans. We invite every private company to reach out and join us in our launch.”
About Eqvista
Eqvista is transforming the private market by bringing unprecedented transparency, accuracy, and agility to private company valuation and equity management. Serving over 23,000 startups and private companies globally, we empower founders and investors to unlock true value and drive smarter decisions. Ranked #1 on G2 and Clutch for both 409A valuations and equity management, Eqvista is trusted by clients ranging from pre-seed startups to unicorns, SMEs, and venture capital firms.
